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Structural investigation of nucleophosmin interaction with the
tumor suppressor Fbw7γ
A Di Matteo1,9, M Franceschini2,3,9, A Paiardini4, A Grottesi5, S Chiarella2,3, S Rocchio6, C Di Natale7, D Marasco7, L Vitagliano8,
C Travaglini-Allocatelli6 and L Federici2,3
Nucleophosmin (NPM1) is a multifunctional nucleolar protein implicated in ribogenesis, centrosome duplication, cell cycle control,
regulation of DNA repair and apoptotic response to stress stimuli. The majority of these functions are played through the
interactions with a variety of protein partners. NPM1 is frequently overexpressed in solid tumors of different histological origin.
Furthermore NPM1 is the most frequently mutated protein in acute myeloid leukemia (AML) patients. Mutations map to the
C-terminal domain and lead to the aberrant and stable localization of the protein in the cytoplasm of leukemic blasts. Among NPM1
protein partners, a pivotal role is played by the tumor suppressor Fbw7γ, an E3-ubiquitin ligase that degrades oncoproteins like
c-MYC, cyclin E, Notch and c-jun. In AML with NPM1 mutations, Fbw7γ is degraded following its abnormal cytosolic delocalization
by mutated NPM1. This mechanism also applies to other tumor suppressors and it has been suggested that it may play a key role in
leukemogenesis. Here we analyse the interaction between NPM1 and Fbw7γ, by identifying the protein surfaces implicated in
recognition and key aminoacids involved. Based on the results of computational methods, we propose a structural model for the
interaction, which is substantiated by experimental findings on several site-directed mutants. We also extend the analysis to two
other NPM1 partners (HIV Tat and CENP-W) and conclude that NPM1 uses the same molecular surface as a platform for recognizing
different protein partners. We suggest that this region of NPM1 may be targeted for cancer treatment.
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INTRODUCTION
Nucleophosmin (NPM1) is an abundant and ubiquitous protein1
mainly localized in nucleoli, where it contributes to their structure
and organization,2,3 but also shuttles between nucleolus and
cytoplasm to perform its functions.4–6 NPM1 has a primary role in
ribosome biogenesis and transport7,8 but also contributes to the
maintenance of genomic stability and DNA repair,9,10 histones
assembly,11,12 centrosome duplication,13,14 cell cycle regulation
and response to stress stimuli.5 The pleiotropic behavior of NPM1
is due to its modular structure consisting of: (i) an N-terminal
oligomerization domain involved in protein–protein interactions
and containing two nuclear export signals (NES);1,4 (ii) an
intrinsically unstructured central region which contains a bipartite
nuclear localization signal (NLS) and (iii) a C-terminal nucleic acid
binding domain where the nucleolar localization signal (NoLS) is
located.6 Multiple post-translational modifications such as phos-
phorylation, acetylation and glutathionylation regulate NPM1
localization and activities.4,5,15
NPM1 is overexpressed in several tumors, including prostate,
liver, gastric, colon, pancreas, glioma and glioblastoma, astro-
cytoma and others.16 Its overexpression often correlates with
mitotic index and metastatization and it was proposed as an
adverse prognostic marker.17,18 The NPM1 gene is also frequently
altered in hematological malignancies arising from chromosomal
translocations. Here, the N-terminal domain of NPM1 is fused to
protein partners such as ALK, RARα and MLF1, giving rise to
oncogenic proteins and haploinsufficency for wild-type NPM1.1
Finally, the NPM1 gene is the most frequently mutated in acute
myeloid leukemia (AML), accounting for 30% of patients.19 AML
mutations are localized at the C-terminal domain of the protein
and cause: (i) the loss of the NoLS, (ii) a severe destabilization or
the complete unfolding of the domain and (iii) the appearance of
a new NES.19 As a result, mutated NPM1 loses affinity for nucleoli
and is found stably and aberrantly in the cytoplasm.19
NPM1 interacts with several protein partners, modulating their
stability and, importantly, it seems to have a fundamental role in
their nucleolar localization. Indeed, most of NPM1 interacting
proteins contain multivalent arginine-rich motifs3 generally found
in NoLS.20 Furthermore, the reduction of NPM1 levels is associated
with the alteration of nucleolar structure.18 All these aspects
substantiate the hypothesis that NPM1 behaves as a hub protein
in nucleoli.2,3 Relevant examples of NPM1 partners include
ribosomal proteins (RPL5, RPS9, RPL23), viral proteins (Rev, Tat)
and many tumor suppressors, including p14ARF, p53 and
Fbw7γ.4,16
NPM1 is required for the nucleolar localization and stabilization
of the isoform γ of Fbw7.21 Fbw7 belongs to the SCF (Skp1, Cullin-
1, Fbox protein) class of E3-ubiquitin ligases22 and has a modular
organization comprising: (i) the D dimerization domain, (ii) the
Fbox domain that binds Skp1 of the SCF complex and (iii) the
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WD40 domain, which recognizes phosphorylated substrates.22 The
Fbw7 gene codes for three protein isoforms (namely α, β and γ)
differing in their N-terminal region and displaying distinct cellular
localization: Fbw7α is nucleoplasmic, Fbw7β is cytoplasmic and
Fbw7γ is nucleolar.23 Many of Fbw7 targets are oncoproteins,
including c-MYC, Notch, Cyclin E and c-Jun22 and therefore
isoforms localization may be instrumental in their regulation
through the compartmentalization of substrates recognition and
degradation. For instance, nucleolar c-Myc is specifically ubiqui-
tinylated by Fbw7γ, thus regulating its growth promoting
activity.23
The alteration of the NPM1/Fbw7γ/c-Myc circuitry was reported
in AML with NPM1 mutations.21 First, it was shown that NPM1 is
necessary for Fbw7γ nucleolar localization and stabilization. As a
consequence, c-Myc ubiquitination and proteasome degradation
is enhanced, thus lowering its levels. Conversely, c-Myc is
stabilized in cells lacking NPM1 and, importantly, in AML blasts
bearing the mutated form of NPM1.21 Indeed, mutations causing
NPM1 cytoplasmic delocalization, do not compromise the inter-
action of NPM1 with Fbw7γ which is also delocalized in the
cytoplasm and degraded.21 A similar delocalization/degradation
mechanism was observed with the tumor suppressor p14ARF.24,25
Overall, different apoptotic responses are compromised by the
selective cytosolic degradation of NPM1 partners. These and other
observations led to the suggestion that the NPM1 region/s
implicated in protein partners recognition may be considered a
target for cancer treatment.16
In this paper we investigate the interaction between NPM1 and
Fbw7γ. We identify, in both proteins, the domains that are
necessary for recognition and the aminoacids involved. We
provide and validate a structural model for the interaction
through protein-peptide docking and molecular dynamics simula-
tions. We also extend this analysis to two other NPM1 interacting
proteins, namely Tat26 and CENP-W,27,28 demonstrating that the
same region of NPM1 recognizes all these proteins, substantiating
the proposed role of NPM1 as a ‘nucleolar hub’. We suggest that
this protein region may be targeted for the treatment of AML with
NPM1 mutations.
RESULTS
NPM1 interacts with the predicted NoLS sequence of Fbw7γ
In an effort to understand the molecular mechanism whereby
Fbw7γ localizes in nucleoli, we carried out a bioinformatic analysis
of Fbw7 isoforms using the NoD algorithm (Nucleolar Localization
Signal Detector; http://www.compbio.dundee.ac.uk/www-nod/
index.jsp) to identify putative nucleolar localization signals (NoLS)
in these proteins (Figures 1a–c). This analysis, which relies on
sequence only, is based on the observation that the NoLS of many
proteins consists of a short motif rich in lysines and arginines
positioned in variably spaced clusters.20 The results showed that
only the N-terminal region of Fbw7γ contains a putative NoLS
(Figures 1c and d), while a partial signal is present in Fbw7α
(nucleoplasmic) (Figures 1a and d) and absent in Fbw7β (cytosolic)
(Figures 1b and d), in agreement with their observed cellular
localization.23 In all three isoforms, this region of the protein is
predicted to be natively unstructured (Figure 1e) and a higher
amount of positive charges within few residues can be
appreciated in the γ isoform with respect to the other two.
Indeed the α and β isoforms contain insertion regions, separating
the two clusters of positive charges found in the γ isoform,
endowed with a higher conformational entropy and smaller
stability, which possibly preclude their recognition as NoLS.
Since Fbw7γ nucleolar localization depends on the presence in
nucleoli of NPM1,21 we hypothesized that its predicted NoLS is the
epitope recognized by NPM1 and we investigated the molecular
determinants of this interaction. To this purpose, we used both
the N-terminal and C-terminal regions of NPM1 (Nter-NPM1,
residues 16-123 and Cter-NPM1, residues 225-294, respectively),
and a peptide encompassing residues 43-56 of the Fbw7γ
sequence (hereafter Fbw7γ*), consisting of the central region of
the Fbw7γ predicted NoLS and containing six positively charged
residues arranged in two clusters (Table 1). The binding process
Figure 1. Identification of nucleolar localization signal (NoLS) in Fbw7. Fbw7 isoforms vary in their N-terminal sequence. The sequences of
Fbw7α (a), Fbw7β (b) and Fbw7γ (c) were subjected to the NoD algorithm in order to identify putative NoLS (Scott et al.,20). The server
identifies a full NoLS in Fbw7γ only (score above 0.8) while only a partial one in Fbw7α. Fbw7γ is known to be nucleolar while Fbw7α is located
in the nucleoplasm. In d the underlined sequences correspond to the putative NoLS. PSIPRED secondary structure predictions for the three
isoforms, in the regions of interest, are shown in e.
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was monitored by equilibrium fluorescence spectroscopy taking
advantage of a dansyl group attached to the peptide N terminus.
Titrations showed an increase of fluorescence dansyl emission
with a blue shift of the emission peak as a function of Nter-NPM1
concentration (see Figure 2a inset). Analysis of the data according
to Equation (1) (Figure 2a) yielded an equilibrium dissociation
constant KD = 3.2 ± 0.6 μM (Table 1). Data were well fitted with a 1:1
peptide/Nter-NPM1 monomer stoichiometry, even though Nter-
NPM1 is pentameric at all concentrations tested in our
experiments.
When the C-terminal domain of NPM1 (Cter-NPM1) was used,
no variation in the emission peak was observed, indicating that it
does not bind Fbw7γ* (Figure 2b). We also performed the same
experiments using dansylated peptides (named unrelated long
and unrelated short) whose sequences are not present in the
Fbw7γ isoform and which are not predicted to be NoLS (Table 1).
No interaction was observed when these peptides were titrated
with Nter-NPM1.
Since it has been reported that NPM1 interacts also with CENP-
W and Tat proteins,26,27 we used the NoD algorithm to identify in
these two proteins their NoLS. Then, dansylated peptides
corresponding to the suggested NoLS regions of the proteins
(peptides CENP-W* and Tat*, respectively) (Table 1) were tested
for their interaction with Nter-NPM1 (Figures 2c and d) and Cter-
NPM1 (Supplementary Figure 1). For both peptides, equilibrium
titrations experiments showed an increase of fluorescence
emission as a function of protein concentration only when the
Nter-NPM1 domain was used (Figures 2c and d), demonstrating
that the interaction specifically involves the N-terminal domain
and that, also in these cases, the predicted NoLS is the binding
epitope recognized by NPM1. The calculated dissociation con-
stants parallel the one obtained for Fbw7γ, being KD = 6.2 ± 0.9 μM
for the Nter-NPM1-CENP-W* interaction and KD = 2.4 ± 0.5 μM for
the Nter-NPM1-Tat* interaction (Table 1).
Identification of Nter-NPM1 residues involved in Fbw7γ
recognition
Nter-NPM1 monomer consists of eight antiparallel β-strands
forming a β-barrel with jelly-roll topology. Five monomers tightly
associate to form a crown shaped pentamer. Since the identified
Nter-NPM1-interacting epitopes are all enriched in positive
Table 1. Dissociation constants for the complexes between Nter-
NPM1 and peptides
Peptide Sequence Nter-NPM1 KD (μM)
Fbw7γ* 43LPFCRRRMKRKLDH56 3.2± 0.6
CENP-W* 14KRKAPRGFLKRVFKRKK30 6.2± 0.9
Tat* 47AGRKKRRQRRRPPQ60 2.4± 0.5
Unrelated long DDEAQTLAKFVLSQK Ni
Unreleted short VLSQK Ni
Abbreviation: Ni, no interaction.
Figure 2. Interaction analysis of NoLS sequences. Peptides corresponding to the putative NoLS were dansylated at their N terminus and
titrated with NPM1 constructs. The static fluorescence spectra are shown in insets, while the experimental maxima and their fit according to
equation 1 (see Materials and Methods) are reported as a function of NPM1 concentrations in the main panels as follows: (a) Interaction
between Fbw7γ* and Nter-NPM1. (b) Interaction between Fbw7γ* and Cter-NPM1. (c) Interaction between CENP-W* and Nter-NPM1.
(d) Interaction between Tat* and Nter-NPM1. Peptides sequences are reported in Table 1.
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charges, we inspected the electrostatic potential surface of Nter-
NPM1 in search for negatively charged patches. Indeed, as shown
in Figure 3, a large negatively charged surface is found, extending
from the pentamer external surface to its central cavity. Among
the residues that contribute to this negatively charged surface, we
focused our attention on three residues, namely D36, E39 and E93,
because they were previously shown to play a role in the
interaction of NPM1 with the tumor suppressor p14ARF.29 To
establish their involvement in binding Fbw7γ*, these residues
were all mutated to alanine, as single or double mutants; a triple
mutant was also prepared. The interaction was measured using
the same protocol as for the wild-type protein (Supplementary
Figure 2) and the resulting KD are reported in Table 2. Mutation to
alanine of D36 and E39 residues led to an increase of KD between
two and three fold. Mutation of E93 had instead a smaller effect.
Consistently, when the double mutants D36A-E93A and E39A-
E93A where tested, observed KD were comparable to those
obtained with the D36A and E39A single mutants, respectively.
When the D36A-E39A double mutant was tested no dramatic
additive effect of the two mutations in destabilizing the
interaction was obtained with KD = 13.5 ± 2.0 μM. Finally, the triple
mutant D36A-E39A-E93A resulted to bind the peptide with a KD
= 22± 3 μM, around seven fold higher than wild type. These data
suggest that though residues D36, E39 and to a minor extent E93,
contribute to the binding energy, the overall binding process is
not entirely dependent on their interactions. Additional residues
are likely involved.
In order to obtain a better description of the interaction and
identify additional residues involved, we performed a molecular
docking analysis of the Nter-NPM1- Fbw7γ* complex. Given the
complexity of docking a long and flexible peptide, the procedure
adopted here was based on a ‘divide and conquer’ approach,
starting from a combinatorial merging of energy-favorable
tripeptides, which were then used as templates for biased-
guided docking (see Materials and Methods for a detailed
description). The top ten scoring docking poses cluster in the
same binding site, with a mean RMSD between poses of 4.3 Å
(Supplementary Figure 3). This is principally the result of the
variable conformations adopted by the C-terminal half of the
peptide, while the N-terminal half appears more fixed. Only a
single peptide was docked onto the Nter-NPM1 pentamer,
nevertheless equivalent docking surfaces are available for the
additional peptides. It is possible that different peptide conforma-
tions, among those selected by the docking procedure, would be
adopted when all Nter-NPM1 monomers are engaged by peptides.
Figures 4a and b show the best scoring docking pose and,
according to this model, Fbw7γ* adopts an extended conforma-
tion and lies with its N-terminal end along the external surface of
the protein while its C-terminal end protrudes into the central
cavity of the pentamer. The majority of interactions are
established with residues belonging to a single Nter-NPM1
monomer, with few contributions from the adjacent one (see
below). Interestingly, although no information regarding interact-
ing residues was imparted to the docking algorithm, all three
residues that we have examined before (D36, D39 and E93) were
found to interact with positively charged residues of the
Fbw7γ* peptide. In particular, in the docking model, D36 forms
a salt bridge with Fbw7γ* R47 (Figure 4c), E39 is salt-bridged to
both R48 and R52 (Figure 4d), while E93 interacts with K53
(Figure 4e).
Inspection of the model showed two additional negatively
charged residues that interact with Fbw7γ*. The first one is E37
that interacts with R47 (Figure 4f); the second one is E121: in this
case the same residue from two different Nter-NPM1 monomers
binds two different residues of the peptide, i.e., K51 and R52
(Figure 4g). Therefore, we mutated these two additional residues
and measured their contribution to the binding energy (Supple-
mentary Figure 2). When E37A and E121A single mutants were
tested, we obtained dissociation constants approximately four-
fold higher than wild-type, similarly to what already seen for the
D36 and E39 mutants (Table 2). Furthermore, starting from the
D36A-E39A-E93A triple mutant, we also prepared two quadruple
mutants and a quintuple one. When the D36A-E37A-E39A-E93A
mutant was tested, we obtained a KD = 151.5 ± 20.5 μM, ≈50-fold
higher than wild type. Likewise, the D36A-E39A-E93A-E121A
mutant showed a KD = 224.3 ± 35.9 μM, ≈70-fold higher than wild
type. Finally, the quintuple mutant displayed negligible affinity for
the peptide, with KD = 653.7 ± 46.9 μM (Table 2).
Overall, these data suggest that the Nter-NPM1-Fbw7γ* binding
energy is dictated by multiple electrostatic contributions through-
out the binding cleft. They also show a non-linear variation of the
KD upon loss of negative charges in Nter-NPM1. In fact the
dissociation constant is relatively stable when only three residues
are mutated, while it markedly increases upon addition of a fourth
mutation. To check the effect of salt on binding we also performed
titrations with wild-type protein and triple, quadruple and
quintuple mutants increasing the ionic strength to 150 mM. We
Figure 3. Electrostatic potential surface analysis of Nter-NPM1. The
crystal structure of human Nter-NPM1 displays a pentameric
organization and was subjected to calculation of the electrostatic
potential surface through the APBS algorithm. Negative and positive
charges are shown in red and blue, respectively. One of the
monomers is shown in ribbon to better highlight the position of
three important acidic residues (D36, D39 and E93), which are
shown in sticks.
Table 2. Dissociation constants for the complexes between the
Fbw7γ* peptide and Nter-NPM1 mutants
Protein KD (μM)
Nter-NPM1 3.2± 0.6
D36A 10.8± 2.6
E37A 12.5± 1.4
E39A 6.2± 1.5
E93A 5.0± 1.6
E121A 13.3± 3.8
D36A-E39A 13.5± 2.0
D36A-E93A 8.4± 1.5
E39A-E93A 7.6± 1.9
D36A-E39A-E93A 22.0± 3.0
D36A-E37A-E39A-E93A 151.5± 20.5
D36A-E39A-E93A-E121A 224.3± 35.9
D36A-E37A-E39A-E93A-E121A 653.7± 46.9
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obtained a general decrease in affinity, as expected, but the trend
observed with the previous experiments was confirmed (Supple-
mentary Table 1).
The same surface of Nter-NPM1 recognizes peptides from
different protein partners
Since the peptides from CENP-W and Tat recognized by Nter-
NPM1 share with Fbw7γ* a high positive charge (Table 1), we
investigated whether the same Nter-NPM1 surface is implicated in
their binding. To this end, we tested the triple, quadruple and
quintuple Nter-NPM1 mutants interaction with the CENP-W*
and Tat* peptides (Supplementary Figure 4). In both cases, and
similarly to what already seen for Fbw7γ*, a clear trend of
increasing dissociation constants is observed as a function of
decreasing negative charges from the triple to the quintuple
mutant (Table 3). These results indicate that the same region of
Nter-NPM1 is responsible for the interaction with different
nucleolar proteins that are all recognized through their
predicted NoLS.
Figure 4. Molecular docking analysis of the Fbw7γ*-Nter-NPM1 interaction. The interaction between Fbw7γ* and Nter-NPM1 investigated
through molecular docking analysis is shown. (a) Nter-NPM1 pentamer is represented in cartoon while the Fbw7γ* peptide is shown in sticks.
(b) The Nter-NPM1 electrostatic surface is shown in a different orientation from a. The peptide, shown in sticks, adopts an extended
conformation with its C-terminal end protruding into the central pentamer cavity. (c) A detail of the interaction played by Nter-NPM1 residue
D36 with Fbw7γ* R47. (d) Nter-NPM1 residue is predicted to interact with both Fbw7γ* R48 and R52 residues. (e) Interaction between Nter-
NPM1 E93 and Fbw7γ* K53. (f) Nter-NPM1 residue E37 is also predicted to interact with Fbw7γ* R47. (g) E121 residues from two different Nter-
NPM1 monomers (the second one is shown in magenta) are predicted to interact with residue K51 and R52 residues.
Table 3. Dissociation constants for the complexes between Nter-
NPM1 selected mutants and the CENP-W* and Tat* peptides
CENP-W* KD (μM) Tat* KD (μM)
Nter-NPM1 6.2± 0.9 2.4± 0.5
D36A-E39A-E93A 18.4± 2.6 11.1± 2.1
D36A-E37A-E39A-E93A 71.4± 9.1 57.4± 7.0
D36A-E39A-E93A-E121A 82.8± 5.6 63.8± 5.0
D36A-E37A-E39A-E93A-E121A 734.0± 158.0 642.6± 70.8
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Figure 5. Molecular dynamics simulations of the interaction between Fbw7γ* and Nter-NPM1 constructs (wild-type and mutants). (a) Root
mean square deviation (RMSD) of Nter-NPM1 and Fbw7γ* Cα atoms as a function of simulation time for WT (black line), triple (red), quadruple
(green) and quintuple (blue), respectively. (b) Average RMSD (root mean square deviation) of Fbw7γ* as calculated for peptide Cα residues for
all simulated systems. Wild-type Nter-NPM1 is shown in black, the triple D36A-E39A-E93A mutant is shown in red, the quadruple D36A-E39A-
E93A-E121 mutant is shown in green, the quintuple D36A-D37A-E39A-E93A-E121 is shown in blue. (c) The position of the peptide at selected
snapshots along the simulation time is shown. Nter-NPM1 wild-type is shown in gray cartoon, Fbw7γ* is shown as a ribbon colored from blue
(simulation start time) to red (simulation end). (d) Same as in c for the interaction between the peptide and the triple D36A-E39A-E93A
mutant. (e) Same as in c for the interaction between the peptide and the quadruple D36A-E39A-E93A-E121 mutant. (f) Same as in c for the
interaction between the peptide and the quintuple D36A-D37A-E39A-E93A-E121 mutant.
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Molecular dynamics simulations
To gain further insights into the structural requirements for
binding, we performed extended molecular dynamics (MD)
simulations on the model structure for the complex between
Fbw7γ* and Nter-NPM1. Given their increasing effect on the
dissociation constant of the complex, we simulated also the
complexes formed by Fbw7γ* with the D36A-E39A-E93A triple
mutant, the D36A-E39A-E93A-E121A quadruple mutant and the
D36A-E37A-E39A-E93A-E121A quintuple mutant. Total simulation
time for all systems was 150 ns. We firstly determined the
convergence and stability of the MD trajectories, in order to
ascertain the validity of conformational sampling in all simulated
systems. To this end, the root mean square deviations (RMSD) of
Cα coordinates of wild type and mutants Nter-NPM1 were
calculated as a function of simulation time (Figure 5a). This
analysis confirmed that the trajectories reached a plateau of the
RMSD, a regime compatible with the conformational drift of a
folded structure and that the simulation time was sufficient to
equilibrate the protein dynamics.
This enabled us to investigate the nature of the Nter-NPM1-
Fbw7γ* interaction by analyzing the relative conformational drift
of Fbw7γ* with respect to the Nter-NPM1 and mutants structures.
Figure 5b shows the averaged RMSD per peptide residue, as
calculated for Cα atoms, for all simulated systems. This analysis
suggests that the Fbw7γ* peptide is stabilized in the binding
surface of wild-type Nter-NPM1 through interactions involving
mainly its N-terminal residues 1–6, which keep a position similar to
the starting structure throughout the whole simulation. This is also
represented in Figure 5c, showing snapshots of the Nter-NPM1-
Fbw7γ* simulation, with the conformation adopted by the peptide
at different times from the beginning (blue) to the end (red) of the
simulation. Differently from the N-terminal end, the C-terminal
region of the peptide, which protrudes inside the central cavity of
the Nter-NPM1 pentamer, populates several conformations along
the simulation time (Figure 5c). Overall, the interaction of wild-
type Nter-NPM1 with Fbw7γ* has the highest RMSD values as
compared with the mutants (Figure 5b). It appears that no single
ion pair is absolutely required for the interaction because adjacent
negative residues can replace the loss of a contact. We speculate
that such binding mode allows the stabilization of the peptide
into the cleft without a significant entropy loss, since many energy
minima can be efficiently explored by the peptide (Figure 5c). This
also explains why single and double NPM1 mutants show only a
weak decrease of the binding affinity for Fbw7γ*.
The analysis of the RMSD over peptide length for the triple,
quadruple and quintuple mutants suggest that in all mutants the
positions explored by the peptide are less variable as compared
with wild type, as shown in Figure 5b which represents a measure
of the average displacement of each peptide Cα atom with
respect to its starting position. Indeed, snapshots of the
simulations at different times indicate that the peptide docks
into the binding surface of the mutants maintaining an overall less
variable conformation along the simulation time (Figures 5d–f).
This observation can be rationalized by taking into account the
hydrophobic interactions played by the newly introduced alanine
residues in the mutants, which are favored and replace many of
the electrostatic interactions previously observed for the wild-type
protein.
Overall we hypothesize that while Fbw7γ* is still able to bind all
NPM1 mutants, the sequential loss of negative charges may be
associated with a significant entropy loss upon binding and a
progressively decreased affinity.
DISCUSSION
In this work we investigated the structural basis of NPM1 protein–
protein associations. We started from the hypothesis that NPM1 is
a ‘nucleolar hub’ protein because it recognizes the NoLS of
different protein partners. In most proteins, the NoLS consists of a
linear stretch of aminoacids, within a natively disordered region,
that is rich in clustered arginines and lysines. Even though a clear
sequence motif cannot be envisaged, such accumulation of
positive charges within few residues is uncommon in proteins and
may be searched for by specific algorithms. We employed one
such algorithm to spot putative NoLS in representative proteins
that are known to interact with NPM1 and to be nucleolar. Then,
we showed that all these epitopes from different proteins were
effectively recognized by Nter-NPM1.
A deeper analysis of the interaction highlighted additional
concepts. First, we showed that at least five negatively charged
residues of Nter-NPM1 contact the peptides. Then, by mutating
them alone and in combinations, we could argue against the
existence of specific hot-spots. Rather, we observed a substantial
stability of the complex when negative charges where replaced
alone or in couples, and appreciated gradually increasing
dissociation constants when three to five residues where mutated
at once. Molecular dynamics simulations provided a plausible
mechanism to interpret these observations and suggested that
the absence of hot-spots is the consequence of the fact that the
loss of one interaction may be compensated by the emergence of
a new one. This is possible because the peptide does not stably
populate a single conformation but moves rather freely within an
extended binding surface provided by Nter-NPM1. Therefore the
loss of a single or a couple of ion-pairs that would destabilize one
conformation may be compensated by the adoption of an
alternative one by the peptide.
Such a model may also explain the amazing versatility of Nter-
NPM1 in binding epitopes from a plethora of other proteins. The
peptides from Fbw7γ, TAT and CENP-W that we identified here, as
well as several other peptides studied by others,3,29,30 are all
positively charged but differ in residue composition, in the
number of charged residues and in their position along the
sequence. How can a single protein recognize them all with similar
affinities? The model we propose implies that all peptides will find,
within the large negatively charged surface provided by the NPM1
pentamer, a multitude of binding poses and will populate those
that are more convenient to their particular distribution of positive
charges. We speculate that such mechanism is at the heart of
NPM1 behavior as a nucleolar hub protein.
But how NPM1 is itself enriched in nucleoli? Previous research
from our and other laboratories has clarified this issue. The NPM1
nucleolar localization signal is unique and consists of W288 and
W290 residues near the C terminus of the protein. These
tryptophans take part to the hydrophobic core of the C-terminal
three-helix bundle domain and their substitution with other
residues leads to the unfolding of the C-terminal domain.31–34 An
unfolded C-terminal domain is in turn unable to interact with
nucleic acids, most prominently G-quadruplex regions at riboso-
mal DNA, resulting in detachment from nucleoli.35–37 Therefore,
the C-terminal domain of NPM1 keeps it at nucleoli while the
N-terminal domain sequesters its binding partners in the same
organelle. When NPM1 moves from nucleoli, because of post-
translational modifications or mutations, the NPM1 protein
partners will be equally displaced, because of their interaction
with the N-terminal domain.
This is ultimately what happens in AML with NPM1 gene
mutations. Mutations cause the unfolding of the C-terminal
domain and consequent loss of affinity for nucleoli. Furthermore,
since a new NES appears in the mutated protein, this is aberrantly
translocated in the cytosol, carrying with itself protein partners like
Fbw7γ and p14ARF, which will be there degraded.21,24 Moreover,
the presence in the cytosol of mutated NPM1 with a functional
N-terminal domain, will result in the establishment of additional
protein–protein interactions. For instance, cytosolic NPM1 binds
and inhibits caspases 6 and 838 and the PTEN deubiquitinating
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enzyme HAUSP, resulting in PTEN cytoplasmic polyubiquitinilation
and degradation.39 Thus a third important tumor suppressor is
also deregulated by the presence of NPM1 in the cytosol.
AML with NPM1 mutation is currently treated with the
administration of several cycles of an anthracycline (daunorubicin,
doxorubicin or others) plus cytarabine.40 Patients carrying NPM1
mutation without the concomitant FLT3-ITD alteration have good
prognosis while, for the latter, chemotherapy is less effective.
However, relapse is frequent and the toxicity of anthracyclines
prevents many patients from its prolonged use. Importantly,
NPM1 mutations are always retained at relapse and this led to the
generally accepted concept that NPM1 should be specifically
targeted in this kind of leukemia.41
Based on the experimental observations we outlined above, we
have recently suggested that an effective strategy to specifically
target AML with NPM1 mutations would be that of interfering with
NPM1 protein–protein interactions.16 Here, we have characterized
the extended surface of Nter-NPM1 involved in protein binding
and thus provided a structural framework to search for small
molecules and/or peptidomimetics targeting this surface. Future
work will be directed at testing these concepts in cellular models
of AML with NPM1 mutations.
MATERIALS AND METHODS
NoLS identification
To identify NoLSs in the proteins of interests to this work we employed the
method described by Scott et al.20 and implemented in the NoD web
server (http://www.compbio.dundee.ac.uk/www-nod/). Briefly, the NoD
algorithm uses an artificial neural network trained on a large set of NoLs
experimentally evaluated, to analyze a sequence in search of local
enrichments of positively charged residues. The sequence of a protein is
scanned in windows of 13 residues with slippage of one amino acid for
each consecutive window and at each window is assigned a score, which
depends on the number of positive charges. When the score is greater
than 0.8, the relative sequence is identified as a predicted NoLs.
Protein constructs
The Nter-NPM1 (residues 16-123) coding sequence was obtained through
gene synthesis (GeneArt, Regensburg, Germany) and cloned into the
expression vector pET28+(a) (Novagen, San Diego, CA, USA) using NdeI
and BamHI restriction enzymes.
Nter-NPM1 mutants were obtained by site-directed mutagenesis using
the Quickchange II Lightning Site-Directed Mutagenesis kit (Stratagene, La
Jolla, CA, USA), following manufacturer’s instructions. Oligonucleotides
used for PCR were obtained from Primm Biotech (Milan, Italy). Forward
oligonucleotides used are reported in Supplementary Table 2.
Protein expression and purification
Escherichia coli cells, BL21(DE3) (Biolabs, Ipswich, MA, USA), transformed with
the expression vectors were grown to A600 ~0.5 in LB medium supplemented
with kanamycin at 37 °C. Expression was induced by addition of 1 mM
isopropyl-1-thio-β-D-galactopyranoside (IPTG) and cells were further grown at
20 °C for 16h. Cells were collected, resuspended in lysis buffer (Buffer A:
20 mM Hepes, pH 7.0, 20 mM imidazole), plus 5 mM MgCl2, 2 μg/ml DNAse
(Roche, Basel, Switzerland), Protease Inhibitor Cocktail Tablet (Roche) and
sonicated. Nucleic acids were digested for 30’ at 37 °C with DNAse I. Proteins
were purified by affinity chromatography (HisTrap FF, GE Healthcare, USA)
using a linear gradient of buffer A plus imidazole (from 20 mM to 1M). Further
purification involved anion exchange chromatography (Q-Sepharose Fast
Flow, GE Healthcare, USA) eluted with NaCl gradient. Fractions containing the
protein, as showed by SDS–PAGE, were collected and concentrated using
Amicon Ultra-15 Centricons with a 3K cut-off (Merck Millipore, Darmstadt,
Germany). The protein solutions were buffer exchanged with Hepes 20 mM,
pH 7.0 and stored at −20 °C. The Cter-NPM1 protein construct (residues 225-
294) was expressed and purified as previously described.36
Equilibrium binding experiments
All experiments were performed at 25 °C in sodium phosphate buffer
20 mM pH 7.2, or in sodium phosphate buffer 20 mM plus 100 mM NaCl pH
7.2 (which sets ionic strength to 150 mM), using a FluoroMax-4 spectro-
fluorometer (Jobin Yvon, Edison, NJ, USA), equipped with a water bath
apparatus. Fbw7γ and CENP-W peptides, functionalized with a dansyl (5-
dimetilamminonaftalen-1-sulphonyl) group at their N terminus, were
purchased from JPT (Germany). Tat peptide was synthesized employing
the solid phase method following standard Fmoc strategies and labeled
with dansyl fluorophore at its N terminus. Crude product was purified by
RP-HPLC applying a linear gradient of 0.1% TFA CH3CN in 0.1% TFA water
from 5% to 65% over 12 min using a semi-preparative 2.2 × 5 cm C18
column at a flow rate of 20 ml/min. Purity and identity were confirmed by
LC–MS analysis.
Titration experiments were conducted with an excitation wavelength of
330 nm while the fluorescence emission spectra were collected in the
range between 350 and 650 nm. Titrations were performed at constant
peptide concentration (5 μM) and varying protein concentrations (from 0 to
200/400 μM). Titrations were performed in triplicate and data, analyzed
with the Graphpad Prism software (https://www.graphpad.com/scientific-
software/prism/), were reported as dissociation constant ± s.d.
Equilibrium binding curves were fitted to the standard quadratic
equation:
F ¼ A½ 0 þ KD þ n
 
2
-
ffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffi
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 2
4
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3
5Bþ C
8<
:
9=
;k ð1Þ
where F is the observed fluorescence signal, n and [A]0 are the total
concentration of non-varied and varied species, respectively, and KD is the
equilibrium dissociation constant. B and C are constants taking into
account the total fluorescence change and fluorescence at [A]0 = 0,
respectively, and k is a term describing the slope of the curve at high
protein concentration42. Whenever possible, under pseudo first-order
conditions, the equation 1 was simplified to:
F ¼ A½ 0
A½ 0 þ KD
ð2Þ
Molecular docking
In order to predict the binding mode of the peptide Nter-PFCRRRMKRKLDH-
Cter to NPM1, tripeptides covering the whole sequence were exhaustively
generated by an ad-hoc Python script.43 The obtained peptides were then
energy minimized by using the Molecular Operating Environment 2009.10
(http://www.chemcomp.com/MOE-Molecular_Operating_Environment.
htm). Steepest descents steps of energy minimization were performed
until the root mean square (RMS) gradient fell below the 0.005 Å default
threshold. The Amber99 force field, a distance-dependent dielectric
constant and a cut-off distance of 40 Å were used during each simulation.
Molecular docking of the tripeptides was carried out by means of
Molegro Virtual Docker (MVD) software (®CLCbio).44 Flexible torsions were
automatically detected by MVD, and manually checked for consistency.
The structure of NPM1 (PDB: 2P1B) was prepared by automatically
assigning bond orders and hybridization, and adding explicit hydrogens,
charges and Tripos atom types. Missing heavy atoms were fixed by
modeling them, using Modeler v.9.845 and PyMod.46 A search space of 20Å
radius, centered on the central cavity of the pentamer (∼4385 Å3) was used
for docking. Cavity detection was carried out by MVD. For each tripeptide,
ten runs were defined. Similar poses (RMSD o1.2 Å) for each tripeptide
were clustered, and the best scoring one was taken as representative.
Other docking parameters were fixed at their default values. Thereafter,
hexamer peptide sequences and their structures were generated and
docked in a second round, by considering the poses of the tripeptides
identified from the first round of docking runs. To this end, the most
energetically favorable poses of the tripeptides were taken as template
groups for template-based dockings. Finally, the 100 top scoring hexamer
peptides poses were taken as template groups for template-based docking
of the whole peptide fragment, using the same above-described approach.
The obtained top scoring complex was subjected to a final energy
minimization, using conjugated gradients until the maximum derivative
was less than 0.0004 kJ mol− 1Å− 1.
Molecular dynamics simulations
MD simulations of complexes were performed starting from the final
refined model obtained in docking calculations. Mutations were intro-
duced with the Pymol software (www.pymol.org).
Nucleophosmin protein–protein interactions
A Di Matteo et al
8
Oncogenesis (2017), 1 – 10
Simulation setup. Calculations were performed using GROMACS 5.0.x
(www.gromacs.org) suite with the Amber99 force field. Initial structures
were immersed in a triclinic simulation box, solvated with SPC water
molecules.47 Ionic strength was adjusted to set the total charge of
simulation box to 0. All simulations were performed in the NVT ensemble
at constant volume and constant temperature (300 K), periodic boundary
conditions were applied. Initial velocities were taken from the Maxwell-
Boltzmann distribution at 300 K. Long-range electrostatic interactions were
calculated using the particle mesh Ewald method48 with a 1.2 nm cut-off
for the real space calculation. A 1.2 nm cut-off was used to estimate Van
der Waals interactions. Pair list was updated every 10 steps. The LINCS
algorithm49 was used to constrain bond lengths; the time step for
integration was 2 fs.
Simulation protocol. Intial structures for all simulations were subjected to
a steepest descent minimizzation cycle to reduce steric hindrance. Then a
restrained MD step-wise procedure was applied to gradually release the
restraints and allow the system to equilibrate at the simulated temperature
of 300 K: applied restrained were 1000, 500 and 250 kJ/mol. Total
simulation time was typically 150 ns. Coordinates were saved every 5 ps.
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